Up a level |
Journal Article
Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041